Schrödinger (SDGR) has put its AI ambitions in focus after launching early access to Bunsen, an agentic AI co-scientist designed to support molecular discovery workflows using its physics-based simulation platform.

The launch of Bunsen comes at a time when Schrödinger's share price has been volatile. A 26.42% 90-day share price return contrasts with a 13.05% decline over 30 days and a 26.99% decline in total shareholder return over the past year, which suggests momentum has been uneven as investors reassess both growth potential and risk.

If Schrödinger's AI initiative has caught your attention, it may be a good moment to broaden your research and see what else is happening across 41 healthcare AI stocks.

Schrödinger now trades at a sizeable discount to both its implied fair value and analyst targets after a sharp pullback. Is that a sensible cushion for execution risk around Bunsen, or is the market leaning too hard on caution?

Most Popular Narrative: 27.6% Undervalued

Analysts following Schrödinger see fair value at $20.88 per share, compared with the last close of $15.12, which puts a spotlight on what is driving that gap.

Increasing demand and improvements in AI-driven software drive higher market penetration, recurring SaaS revenues, and stronger operating margins.

Want to see how this AI and software story supports that valuation gap? The narrative focuses on compound revenue growth, margin rebuild, and a richer future earnings multiple. The exact mix of those assumptions might surprise you.

Result: Fair Value of $20.88 (UNDERVALUED)

However, you still need to weigh execution risks, including pressure on software margins from predictive toxicology investment, as well as reliance on volatile milestone and royalty revenue for Schrödinger.

Another View on Schrödinger’s Valuation

The SWS DCF model paints a different picture for Schrödinger. At a share price of $15.12 and an estimated future cash flow value of $40.78, the stock is described as trading well below that model fair value. That raises a clear question. Is the market underestimating the long term cash generation story, or are the DCF assumptions too generous?

Next Steps

Mixed messages on Schrödinger so far? Use this as a springboard to check the key data points and form your own view with the full 2 key rewards and 1 important warning sign

Looking for more ideas beyond Schrödinger?

If Schrödinger has sharpened your curiosity, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your own investing style.

• Spot potential value opportunities before the crowd by checking companies that screen as 49 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks in the 85 resilient stocks with low risk scores that aim to balance return potential with lower risk scores.
• Hunt for lesser-known opportunities by scanning the screener containing 21 high quality undiscovered gems that combine quality fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.